Abstract

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF BEMPEDOIC ACID AND EZETIMIBE IN PURE AND PHARMACEUTICAL DOSAGE FORM- AN OVERVIEW

Aakash Suresh*, Anbarasi Balakrishnan, Vijayamirtharaj Ramaswamy and Senthil Kumar Natesan

ABSTRACT

Adenosine triphosphate citrate lyase (ACL) inhibitors of the highest Caliber include Bempedoic acid and Ezetimibe. In individuals who are resistant to statins, Bempedoic acid is used to reduce LDL cholesterol levels. When taken alone or in conjunction with other medications that decrease cholesterol, Ezetimibe is used to treat hyperlipidemia. The combination medicine NEXLIZET, which contains Bempedoic acid and Ezetimibe, was authorized on February 26, 2020. The combo drug is used to treat elevated cholesterol. To treat elevated blood levels of triglycerides and cholesterol, the combination is taken in conjunction with a healthy diet. In the present study methods developed and used for determination as single and combination in bulk medicines, pharmaceutical formulation, and biological fluids have been examined, along with a scan of literature and reviews published in major analytical and pharmaceutical publications. The analytical techniques include liquid chromatography-tandem mass spectroscopy, spectrophotometric techniques, and chromatographic techniques like HPLC, RP-HPLC, HPTLC and etc.

Keywords: Ezetimibe, Bempedoic acid, Hyperlipidaemia, UV, HPLC, and Method Development and Validation.